Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximabPaolo Ghia, Mazyar Shadman, Jason C. Paik et al.|Current Medical Research and Opinion|2023Cited by 3
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLLMazyar Shadman, Talha Munir, Tian Tian et al.|Blood Advances|2026Cited by 1
CLL-1029: A Network Meta-Analysis of Efficacy of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-Naïve Chronic Lymphocytic LeukemiaMazyar Shadman, Talha Munir, Keri Yang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0